Canada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not Restarted

Canada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not Restarted

Add Canada to the list of countries reviewing AstraZeneca's (NYSE: AZN) coronavirus vaccine, AZD1222, before the phase 3 clinical trial is complete. The European Medicines Agency is also conducting a rolling review of the vaccine. AstraZeneca can also submit preclinical animal safety data before the phase 3 data is ready to be submitted.